AMD1抗体

+ +

•  

   

     Western blot analysis of HLAA in K562, Hela lysates using HLA A antibody.    

  
  

•  

   

     Immunocytochemistry analysis of HLA A(green) in Hela using HLA A antibody,and DAPI(blue)    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human colon cancer using HLA A antibody. High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

AMD1 (adenosylmethionine decarboxylase 1) is a key enzyme in the polyamine biosynthesis pathway, catalyzing the decarboxylation of S-adenosylmethionine (SAM) to produce decarboxylated SAM. This reaction provides the aminopropyl group required for synthesizing spermidine and spermine, polyamines essential for cell proliferation, differentiation, and stress response. Dysregulation of AMD1 has been implicated in various pathological conditions, including cancer, neurodegenerative diseases, and metabolic disorders, due to its role in maintaining polyamine homeostasis.

AMD1 antibodies are vital tools for studying the expression, localization, and function of AMD1 in biological systems. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to quantify AMD1 levels in tissues or cell lines, often revealing elevated expression in certain cancers (e.g., colorectal, liver) linked to aggressive tumor behavior. Researchers also employ these antibodies to explore AMD1’s interaction with regulatory proteins or its response to therapeutic agents targeting polyamine metabolism.

The development of AMD1-specific antibodies has advanced research into polyamine-related therapies, particularly inhibitors aiming to disrupt cancer cell growth. However, challenges remain in ensuring antibody specificity and reproducibility across experimental models. Ongoing studies continue to clarify AMD1’s dual roles in cell survival and stress adaptation, highlighting its potential as a diagnostic or therapeutic target.